Sununary. Hypertriglyceridaemia and insulin resistance are closely associated but it is unknown whether hypertriglyceridaemia per se contributes to insulin resistance. In the present study we examined whether gemfibrozil, by lowering triglyceride levels, improves the glucoregulatory and antilipolytic action of insulin in Type 2 (non-insulin-dependent) diabetes mellitus. Twenty patients were randomly allocated to receive either placebo or gemfibrozi11200 mg daily for 12 weeks in a double-blind study. Very low density lipoprotein triglyceride levels decreased in the gemfibrozil group by 42_+12% (p < 0.01). Gemfibrozil had no effect on the diurnal concentration of non-esterified fatty acids (NEFA). At the randomization HbAlc levels were comparable (7.6 + 0.3 vs 7.8 _+ 0.2 %, NS) and increased slightly both in the gemfibrozil (8.2_+ 0.4 %, p < 0.05) and placebo groups (8.0 -+ 0.3 %, NS). Preand post-treatment diurnal glucose and insulin concentrations remained unchanged. Basal pre-and post-treatment hepatic glucose production rates were comparable in both groups and similarly suppressed by insulin. Rate of whole body glucose disposal during a low-dose insulin infusion (serum insulin -90 pmol/1) (pre-vs post-gemfibrozil 11.9 + 1.1 vs 11.1+0.7, pre-vs post-placebo 9.9+1.1 vs 10.8+ 0.8 gmol. kg -z. min -1, NS for both) and a high-dose insulin infusion (serum insulin -500 pmol/1) (16.2 + 1.7 vs 17.7 + 2.7, 17.1 + 4.2 vs 17.4 + 2.9 gmol. kg -1. min-% respectively, NS for both) remained unchanged. Basal pre-and post-treatment NEFA turnover rates were comparable in both groups and similarly suppressed by insulin. Also rates of total lipid oxidation, plasma NEFA oxidation and non-oxidative NEFA metabolism remained unchanged in both groups. We conclude that gemfibrozil effectively lowers serum triglycerides but has no effect on insulin sensitivity of glucose and NEFA metabolism. The data suggest that hypertriglyceridaemia is a consequence rather than a cause of insulin resistance in Type 2 diabetic patients.
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Hypertriglyceridaemia, a decreased high density lipoprotein (HDL) cholesterol concentration, hyperinsulinaemia and insulin resistance are metabolic abnormalities which co-exist in Type 2 (non-insulin-dependent) diabetic patients. The concentration of serum triglycerides is correlated with insulin resistance in normolipidaemic subjects with normal glucose tolerance, in subjects with impaired glucose tolerance and in Type 2 diabetic patients [1] [2] [3] . Subjects with endogenous hypertriglyceridaemia and normal glucose tolerance also exhibit resistance to both the antilipolytic and glucoregulatory actions of insulin [2] [3] [4] [5] . It is, however, unclear whether hypertriglyceridaemia is a consequence of insulin resistance or whether it has a direct deleterious action on glucose metabolism.
It is well-established that insulin has multiple sites of action on very low density lipoprotein (VLDL) production in the fiver [6] . Thus, insulin resistance could lead to increased VLDL production and elevation of serum triglycerides [7, 8] . Indeed, recent epidemiological data disclosed that insulin resistance precedes the development of hypertriglyceridaemia [9] . Since suppression of non-esterified fatty acids (NEFA) by insulin is impaired not only in Type 2 diabetic patients [10] but also in hypertriglyceridaemic subjects [2] an increased availability of circulating NEFA could impair insulin action on glucose metabolism in both disorders. Notably, elevation of triglyceride and NEFA concentrations by Intralipid inhibits insulinstimulated glucose uptake during hyperinsulinaemia but it is unclear whether NEFA or triglycerides mediate this effect [11, 12] .
Gemfibrozil exerts multiple actions on VLDL metabofism. The major action of gemfibrozil is to enhance the hydrolysis of triglyceride rich particles by increasing lipoprotein lipase activity [13] . Kinetic data suggest that the drug also inhibits VLDL triglyceride production [14] . However, the mechanisms by which fibric acid derivates de- [15] suggested that both the turnover rate and the mass of plasma NEFA decrease during gemfibrozil therapy indicating that gemfibrozil might be antilipolytic. Studies with isolated adipocytes have also indicated that gemfibrozil is antilipolytic [16, 17] . If gemfibrozil has indeed antilipolytic action this could explain its inhibitory effect on VLDL triglyceride synthesis.
The maj or aim of the present study was to test whether lowering of serum triglycerides by gemfibrozil affects the glucoregulatory effect of insulin in Type 2 diabetic patients with moderate hypertriglyceridaemia. In addition we studied whether gemfibrozil modulates NEFA metabolism or the antilipotytic action of insulin. If this were the case, it might be possible to treat both hypertriglyceridaemia and hyperglycaemia in these patients with a single drug.
Patients and methods
Patients. Twenty Type 2 diabetic patients participated in the study. Their clinical characteristics are shown in Table 1 . Patients with serum triglycerides between 1.50 to 4.50 mmol/1 were considered acceptable for the study. This range of triglycerides was selected based on our previous data which demonstrated an inverse relationship between serum triglycerides lower than 4.5 mmol/1 and glucose disposal at physiological insulin concentrations [1, 2] . The mean serum triglyceride concentration of the patients at the 6-week pre-treatment visit was 2.85 + 0.30 mmol/1. Endocrine and other disorders that could influence glycaemic control or lipoprotein metabolism were excluded by history and physical examination, and by liver, kidney, and thyroid function tests. All patients were treated with oral hypoglycaemic agents (gemfibrozil group: sulphonylurea n = 4, sulphonylurea and biguanide n = 5, sulphonylurea, bignanide and guarem n = 1, placebo group: sulphonylurea n = 5, sulphonylurea and biguanide n = 2, sulphonylurea and guarem n = 2, sulphonylurea, biguanide and guarem n = 1). The oral antidiabetic agents were continued unchanged throughout the study. The patients had no signs of clinically significant micro-or macrovascular diabetic complications. The nature and potential risks of the study were explained in detail to each patient before they gave their informed consent to participate. The study protocol was approved by the Ethical Committee of the Helsinki University Central Hospital.
Study design. During the 6-week pre-treatment period, all subjects received two tablets of placebo twice dally (single blind). Glycaemic control and serum lipid concentrations were measured at 3 and 6 weeks during the pre-treatment period. At these visits the patients Laboratory tests during the 6-week pre-treatment and 12-week treatmentperiod. At each visit blood was withdrawn for determination of the fasting blood glucose, HbAlc, serum triglyceride and total cholesterol concentrations. At 0 and 12 weeks the concentrations of serum VLDL triglycerides, low density lipoprotein (LDL) cholesterol and HDL cholesterol were also measured.
Metabolic tests at 0 and 12 weeks. On day i after admission, blood glucose, serum insulin, triglyceride and plasma NEFA concentrations were determined in blood samples taken at 07. 30,11.30, 12 .00, 16.00, 20.00, 24.00, 04.00, and 08.00 hours. Blood pressure was measured after 5 to 10 min rest in the sitting position with a random zero sphygmomanometer (Random Zero Sphygmomanometer; Hawksley & Sons, Lancing, UK).
On day 2, after an overnight fast, glucose and NEFA kinetics and oxidation rates were measured between 08.00 and 13.00 hours as depicted in Figure 1 . Each study consisted of a basal period (0-60 rain) and two hyperinsulinaemic periods (60-180 min, low-dose insulin infusion; 180-300 min, high-dose insulin infusion). Rates of glucose appearance (Ra) and disappearance (Rd) were determined using an infusion of [3-3H] glucose, and plasma NEFA kinetics using [1-14C] palmitate-labelled albumin. During hyperinsulinaemia, plasma glucose was maintained constant using the insulin clamp technique as previously described [18, 19] . These measurements were combined with indirect calorimetry to determine substrate oxidation rates as well as with collection of expired CO2 for calculation of plasma NEFA oxidation as described below. .00 hours (from -210 to 180 min). We chose not to measure hepatic glucose production (HGP) during high-dose insulin infusion since our previous studies [20] as well as those of the others had shown that reliable measurements cannot be obtained if glucose specific activity changes rapidly. When measured in normal subjects under conditions where glucose specific activity is held constant, HGP is entirely suppressed in the presence of hyperinsufinaemia comparable to that in the present study [21] but this does not necessarily imply normal suppression in patients with Type 2 diabetes. Thus, the rate of glucose infused during the high-dose insulin infusion reflects overall insulin resistance rather than merely peripheral insulin resistance. The priming dose, which was given as a bolus during 10 min, was adjusted according to the fasting blood glucose concentration on day 1 to achieve constant glucose specific activity [22] . Glucose specific activity [23, 24] was measm'ed at 0, 30, 60, 150 and 180 min. At 60 min, a primed continuous infusion of insulin (0.1 mU. kg-l.min -1, Actrapid HM, Novo, Copenhagen, Denmark) was started to increase and maintain serum insulin at -90 pmol/1 [18] . Plasma glucose was measured every 5 to 10 min in blood samples taken from arterialized venous blood, and 20% glucose was infused to maintain blood glucose at its fasting level. At 180 min, the serum insulin concentration was increased and maintained at -500 pmol/1 (insulin infusion rate of 1.0 mU. kgl -min 1). Plasma glucose concentration was allowed to reach normoglycaemia and it was kept constant thereafter. Serum free insulin concentrations were measured at 0, 60, 90,150, 180, 210, 270 and 300 min.
Glucose Ra and R4 were calculated according the non-steadystate equation of Steele [23] , assuming a glucose distribution volume of 200 ml/kg and a pool fraction of 0.65. Use of this model leads, under some conditions, to underestimation of glucose R~ and R4 [20] . To avoid these errors the basal period lasted 270 min instead of the usual 120--180 min.
Respiratory exchange measurements. Indirect calorimetry measurements were performed with a computerized flow-through canopy gas analyser system (Deltatrac Metabolic Monitor; Datex Helsinki, Finland) as depicted in Figure 1 and as previously described in detail [12, 24, 25] . The protein oxidation rate was estimated from urinary urea nitrogen excretion. Non-oxidative glucose Ra was defined as the difference between total Rd and oxidative Rd.
Plasma NEFA turnover and oxidation measurements. [1 -14C] palmirate (New England Nuclear, Boston, Mass, USA) complexed to albumin (SPR, Helsinki, Finland) was used for measurement of plasma NEFA turnover, as previously described [26] . A priming dose of 6 ~tCi [1-14C]palmitate-albumin was given at 0 min, and 0.1 ~tCi/min of [1 -~4C]palmitate-albumin solution was infused between 0-300 min. Use of these isotope doses results in constant plasma NEFA specific activity within 30 min [26] . Serum triglycerides, plasma glycerol [27] and NEFA concentrations [28] and NEFA specific activity [26] were measured in blood samples taken at 0, 30, 60, 150,180,270 and 300 min.
To determine the rate of plasma NEFA oxidation during the [1 -14C]palmitate infusion, the specific activity of expired air CO2 was measured as depicted in Figure I and as previously described [24, 29, 30] . The bicarbonate pool was primed with 5 gCi of NaH14CO3 (New England Nuclear) given as a bolus at 0 min [29] . Plasma NEFA oxidation could be reliably determined in 12 of 20 patients in whom constant CO2 specific activity was achieved.
The rate of plasma NEFA oxidation was calculated as follows: plasma NEFA oxidation rate (gmol.kg-l.min -1) = SA 14CO2-Vco2/(C x SA[14C]NEFA) where SA 14CO 2 is the specific activity of CO2 in expired air (dpm/~tmol), Vco2 is the total CO2 production rate (gmol. kg-1. min-1), SA[14C]NEFA is the specific activity of [14C]NEFA in plasma (dpm/gmol), and C=0.81, the retention factor to correct for labelled CO2 retained in the bicarbonate pool [29] . Use of this technique to determine plasma NEFA oxidation has recently been reval• [30] . Non-plasma NEFA oxidation [10, 24, 30] which is the difference between total lipid oxidation and plasma NEFA oxidation expressed as palmitate oxidation, and NEFA turnover [24, [31] [32] [33] were calculated as previously described in detail.
Analytical procedures
Blood glucose concentrations were measured by the glucose dehydrogenase method (Gluc-DH; Merck Oy, Darmstadt, FRG). During the metabolic test on day 2 glucose was determined in plasma by the glucose oxidase method [34] , using the Beckman Glucose Analyzer II (Beckman Instruments, Fullerton, Calif., USA). Serum insulin concentrations were determined by RIA [35] using the Phadeseph insulin RIA kit (Pharmacia, Uppsala, Sweden). Serum free insulin concentrations were determined by RIA [35] after precipitation with polyethylene glycol. Serum C-peptide was determined by RIA using the RIA-mat C-Peptid II kit (BYK-Sangtec Diagnostica GmbH, Frankfurt, FRG; [36] ). HbAlc (reference range 4.0-6.0 %) was measured with ion exchange high performance liquid chromatography using the fully automated Glycosylated Hemoglobin Analyzer System (Bio-Rad, Richmond, Calif., USA; [37] ). Serum and lipoprotein cholesterol and triglyceride concentrations were determined enzymatically (kit nos. 0722138 and 0715166; Hoffmann-La Roche, Basel, Switzerland) with an automated Cobas Mira analyser (Hoffmann-La Roche). VLDL, LDL and HDL were spearated by ultracentrifugation at 100,000 g in a Beckman L7-70 ultracentrifuge as previously described in detail [38] .
Statistical analysis
Comparisons between 0 and 12 week study occasions, and between study groups were performed using BMDP program 4V for analysis of variance and covariance with repeated measures, followed by 
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Serum lipids.
At randomization, serum triglyceride, total HDL and LDL cholesterol concentrations were comparable in the gemfibrozil and placebo groups. Fasting VLDL triglycerides fell in the gemfibrozil group by 42_+12% (p <0.01), but remained unchanged in the placebo group (Table 2) . Serum HDL cholesterol also rose slightly in the gemfibrozil group (p < 0.05) but not in the placebo group ( Table 2 ). The serum LDL cholesterol concentration rose slightly but not significantly in the gemfibrozil group whereas there was a modest decrease in the placebo group. The LDL/HDL cholesterol and total/HDL cholesterol ratios remained unchanged in both groups (Table 2 ). Figure 2 shows 24-h profiles of triglyceride and plasma NEFA concentrations. The mean 24-h pre-treatment triglyceride concentration was 3.24 +0.29 mmol/1 in the gemfibrozil group and 3.42 _+0.43 mmol/1 (NS) in the placebo group. During gemfibrozil treatment the mean 24-h serum triglyceride concentration fell by 29 _+ 9 % (p < 0.01). In the placebo group there was a trend towards an increase in serum triglycerides. There were no differences in the pre-vs post-treatment mean concentrations of 24-h NEFA in the gemfibrozil group (384+23 vs 441 + 26 gmol/1, NS) or in the placebo group (450 + 45 vs 534 + 81 gmol/1, NS, respectively).
Glycaemic control and serum insulin concentrations.
At randomization the HbAlc levels were comparable in both groups (Table 1) (Fig.4) . Serum free insulin concentrations were similar between the two groups during the insulin infusions (Fig. 4) .
Glucose metabolism. Pre-treatment rates of hepatic glucose production (glucose Ra) in the basal state were similar in the gemfibrozil and placebo groups (12.3 + 5.0 and 12.1 + 1.1 gmol. kg-1. rain-a, NS) and did not change during treatment (12.7 + 0.7 and 11.1 + 1.0 gmol. kg 1. min-1, NS, respectively, Table 4 ). Also, the low-dose insulin infusion suppressed hepatic glucose production similarly in both groups (pre-vs post-gemfibrozil 9.0 + 1.0 vs 8.5 + 1.0, pre-vs post-placebo 7.1+1.2 vs 7.4_+1.0~mol. kg-1. rain -1, NS for both, Table 4 ). The pre-and post-treatment rates of total glucose disposal (glucose Rd) in the basal state, and during the lowand high-dose insulin infusions were similar in both groups (Table 4) . Since the glucose level was slightly different in the pre-and post-treatment studies during the low-dose insulin infusion, the glucose clearance rates (glucose Ra divided by the ambient glucose concentration) were calculated. The glucose clearance rates also remained unchanged (data not shown). In both groups the basal rates of glucose oxidation and non-oxidative glucose disposal (glucose Re -oxidation) did not change during the treatment period. Also during the low-and high-dose insulin infusion, the pre-and post-treatment rates of glucose oxidation and non-oxidative glucose disposal were similar (Table 4) .
NEFA metabolism. The plasma NEFA turnover rates were equal in both groups (Table 3) . Insulin suppressed plasma NEFA turnover rates in an identical fashion in both groups. Overall the plasma NEFA concentrations paralleled the changes in plasma NEFA turnover rates (Table 3) .
Pre-and post-treatment rates of total lipid oxidation, plasma and non-plasma NEFA oxidation, and non-oxidative NEFA metabolism were similar in the gemfibrozil group in the basal state as well as during the low-and highdose insulin infusions. In the placebo group, the pre-and post-treatment basal lipid metabolism were similar. During the low-dose insulin infusion total lipid oxidation tended to increase (NS) and a slight increase was seen in non-plasma NEFA oxidation while plasma NEFA oxidation did not change after treatment period. During the high-dose insulin infusion the pre-and post-treatment rates of lipid metabolism were similar in the placebo group (Table 3) .
Serum triglyceride and plasma glycerol concentrations during the metabolic tests. Serum triglycerides (data not shown) and plasma glycerol concentrations were suppressed similarly by insulin in both groups and in both studies. In the gemfibrozil group pre-vs post-treatment plasma glycerol concentrations in the basal state were 90 + 7 vs 81 _+ 7 gmol/1 (NS) and were decreased by the low-dose insulin infusion to 63 + 5 vs 55 + 5 gmol/1 (NS), and by the high-dose insulin infusion to 44+4 vs 37+4gmol/1 (NS), respectively. The corresponding pre-vs post-treatment concentrations in the placebo group were 75+5 vs 85+8gmol/1 (NS), 63+7 vs 64 + 6 gmol/1 (NS) and 39 + 4 vs 47 + 7 ~mol/1 (NS), respectively. Interrelations between glucose and lipid metabolism. Basal lipid oxidation at week 0 correlated positively with plasma NEFA concentrations (r = 0.46, p < 0.05), the plasma NEFA turnover rate (r =0.55, p <0.01) and plasma NEFA oxidation (r = 0.70, p < 0.01). Basal glucose oxidation rates displayed an inverse correlation with lipid oxidation (r = -0.87, p < 0,001) and non-oxidative NEFA metabolism (r = -0.59, p < 0.05). There were no correlations between fasting serum total or VLDL triglycerides and basal lipid oxidation or insulin-stimulated glucose disposal at week 0.No correIationbetween HDL-cholesterol concentration and insulin-stimulated glucose disposal at baseline was found.
Adverse effects. The serum creatine kinase concentration increased from 207 to 515 U/1 (reference range 0-270 U/1 for men) in one patient after 8 weeks of gemfibrozil therapy, but was normal after 12 weeks of gemfibrozil therapy (143 U/l). The increment in serum creatine kinase was more likely to be caused by heavy muscle exercise than by gemfibrozil, No other adverse effects emerged.
Discussion
The relationships between insulin resistance, hypertriglyceridaemia and low HDL cholesterol are still unclear in Type 2 diabetes. The obvious question is what are the underlying mechanisms for these associations: is hypertriglyceridaemia and a low HDL cholesterol concentration a cause or a consequence of the insulin resistance found in Type 2 diabetes. To try to answer this question gemfibrozil was used to lower the concentration of serum triglycerides in Type 2 diabetic patients in a randomized double-blind placebo controlled study. Although the lipid lowering effect of gemfibrozil is well-documented in non-diabetic subjects, its efficacy in diabetic subjects has not been well-established. In this trial gemfbrozil caused a significant reduction of both fasting total and VLDL and of postprandial triglyceride concentrations and a small but significant rise of HDL cholesterol concentration. The data are consistent with recent observations by Garg and Grundy [39] and Shen et al. [40] . The elevation of LDL cholesterol in the gemfibroziI group was not unexpected but the lowering of LDL cholesterol in the placebo group was puzzling as discussed elsewhere (Lahdenperfi S, Tilly-Kiesi M, Vuorinen-Markkola H, Taskinen M-R, unpublished data). Gemfibrozil reduces LDL cholesterol in subjects belonging to the lowest tertiles of serum triglycerides but raises LDL cholesterol in subjects with moderate hypertriglyceridaemia [41] . Recently fibrates have been shown to shift the distribution of circulating LDL towards larger and less dense particles [42] [43] [44] , which are considered to be less atherogenic than the small dense LDL particles [45] . Likewise, in the present study LDL particle size increased as reported in detail elsewhere (Lahdenperfi S et al., unpubfished data).
Recent studies have suggested that glycaemic control is not affected by gemfibrozil [39, 40] . Clofibrate and bezafbrate have been reported to either slightly improve or to have no effect on glycaemic control in Type 2 diabetic patients [46] [47] [48] . In the present study HbAlc levels tended to increase slightly in both groups but the increment was significant only in the gemfibrozil group. This was partly due to one patient in the gemfibrozil group who developed secondary failure during the treatment period. His HbAlc increased from 7.9 % to 10.1% during the study period and insulin treatment was initiated after the study. The fact that fasting blood glucose or insulin and 24-h glucose or insulin profiles determined in the standardized circumstances did not change in either group indicate that overall gemfibrozil had no effect on glycaemic control.
The present data demonstrate that gemfibrozil has no effect on either the glucoregulatory or antilipolytic action of insulin in Type 2 diabetic patients with moderate hypertriglyceridaemia although it significantly reduces the concentration of serum triglycerides. The results are consistent with the recent observation by Shen et al. [40] . However, when Shen et al. subgrouped the patients on the basis of initial glycaemic control the patients with fair control (fasting plasma glucose > 9.0 mmol/1) demonstrated a slight improvement of insulin sensitivity. Since the study was not controlled it is impossible to exclude that the effect reflects only the intensity of investigator involvement in patient management. Steiner [49] found an improved insulin sensitivity determined by oral glucose tolerance test in non-diabetic subjects treated with 167 gemfibrozil. However, the improvement was observed only in those subjects whose triglycerides decreased more than 1.7 mmol/1. The present data do not exclude the possibility that correction of severe hypertriglyceridaemia may improve insulin sensitivity. On the other hand insulin sensitivity (measured using the insulin clamp technique) has r.emained unchanged during bezafbrate treatment despite the marked lowering of total and VLDL triglyceride levels [48, 50] .
The present study also provides information, derived from indirect calorimetry, on the intracellular fate of glucose during gemfibrozil vs placebo treatments. The data show that gemfibrozil had no effect on either basal or insulin-stimulated glucose oxidation or non-oxidative metabolism. Unlike previous studies, we could not find any correlation between baseline serum triglycerides and insulin-stimulated glucose disposal. However, our patients were in moderate metabolic control and consequently variation in these parameters was relatively small. Moreover lowering of triglycerides did not modulate lipid oxidation in the basal state or during insulin infusion as would be expected if hypertriglyceridaemia would increase lipid oxidation.
The second aim of this study was to test if gemfibrozil has any antilipolytic action. Theoretically, lowering of plasma NEFA concentrations could improve insulin sensitivity of glucose utilization via substrate competition between glucose and lipids [11, 12, 51, 52] . In the present study we could not observe any differences of 24-h plasma NEFA profiles between gemfibrozil and placebo groups. Also, rates of NEFA and lipid oxidation in the basal state and during the insulin infusion were not influenced by gemfibrozil in the present study. Thus, the data do not support the concept that gemfibrozil would have been antilipolytic in man.
In conclusion the present data support the concept, that lowering of serum triglycerides does not improve insulin sensitivity in Type 2 diabetic patients with moderate hypertriglyceridaemia. However, gemfibrozil can be advocated for treatment of lipid abnormalities in Type 2 diabetic patients because it has benefcial action on both hypertriglyceridaemia and low HDL cholesterol which are the major lipid abnormalities in Type 2 diabetes. 
